Naringenin inhibits allergen‑induced airway remodeling in a murine model of asthma

Shi,Ying; Tan,Yan; Mao,Shan; Gu,Wei

doi:10.3892/mmr.2014.1940

Naringenin inhibits allergen‑induced airway remodeling in a murine model of asthma

Authors:
- Ying Shi
- Yan Tan
- Shan Mao
- Wei Gu
View Affiliations

Affiliations: Department of Respiratory Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu 210006, P.R. China
Published online on: February 10, 2014 https://doi.org/10.3892/mmr.2014.1940
Pages: 1204-1208

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The flavonoid naringenin has been shown to attenuate airway inflammation and airway hyper‑reactivity in acute murine models of asthma. The purpose of this study was to investigate the effects of naringenin in allergen‑induced airway remodeling in mice. Ovalbumin (OVA)‑sensitized mice were challenged with OVA for 8 weeks to produce a model of chronic asthma. Airway hyper-responsiveness (AHR), inflammation and remodeling were evaluated in mice receiving naringenin prior to OVA challenge. Compared to OVA-sensitized and -challenged mice, those treated with naringenin showed markedly attenuated chronic inflammation, persistent AHR and airway remodeling. In addition, naringenin treatment caused a significant reduction in the levels of total serum IgE and of T helper 2 (Th2) cytokines in the bronchoalveolar lavage fluid (BALF). Naringenin may thus delay the progression of airway remodeling, providing a potential treatment for asthma.

View Figures

View References

1	Bousquet J, Clark TJ, Hurd S, Khaltaev N, Lenfant C, O’Byrne P and Sheffer A: GINA guidelines on asthma and beyond. Allergy. 62:102–112. 2007. View Article : Google Scholar
2	Bousquet J, Jeffery PK, Busse WW, Johnson M and Vignola AM: Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med. 161:1720–1745. 2000. View Article : Google Scholar : PubMed/NCBI
3	Vignola AM, Gagliardo R, Siena A, Chiappara G, Bonsignore MR, Bousquet J and Bonsignore G: Airway remodeling in the pathogenesis of asthma. Curr Allergy Asthma Rep. 1:108–115. 2001. View Article : Google Scholar
4	Tagaya E and Tamaoki J: Mechanisms of airway remodeling in asthma. Allergol Int. 56:331–340. 2007. View Article : Google Scholar : PubMed/NCBI
5	Warner SM and Knight DA: Airway modeling and remodeling in the pathogenesis of asthma. Curr Opin Allergy Clin Immunol. 8:44–48. 2008. View Article : Google Scholar : PubMed/NCBI
6	Benayoun L and Pretolani M: Airway remodeling in asthma: mechanisms and therapeutic perspectives. Med Sci (Paris). 19:319–326. 2003.(In French).
7	Park HY, Kim GY and Choi YH: Naringenin attenuates the release of pro-inflammatory mediators from lipopolysaccharide-stimulated BV2 microglia by inactivating nuclear factor-κB and inhibiting mitogen-activated protein kinases. Int J Mol Med. 30:204–210. 2012.PubMed/NCBI
8	Anand K, Sarkar A, Kumar A, et al: Combinatorial antitumor effect of naringenin and curcumin elicit angioinhibitory activities in vivo. Nutr Cancer. 64:714–724. 2012. View Article : Google Scholar : PubMed/NCBI
9	Shi Y, Dai J, Liu H, et al: Naringenin inhibits allergen-induced airway inflammation and airway responsiveness and inhibits NF-κB activity in a murine model of asthma. Can J Physiol Pharmacol. 87:729–735. 2009.PubMed/NCBI
10	Cayci C, Wahlquist TC, Seckin SI, et al: Naringenin inhibits neointimal hyperplasia following arterial reconstruction with interpositional vein graft. Ann Plast Surg. 64:105–113. 2010. View Article : Google Scholar : PubMed/NCBI
11	Chen S, Ding Y, Tao W, Zhang W, Liang T and Liu C: Naringenin inhibits TNF-α induced VSMC proliferation and migration via induction of HO-1. Food Chem Toxicol. 50:3025–3031. 2012.
12	Cho JY, Miller M, Baek KJ, et al: Inhibition of airway remodeling in IL-5-deficient mice. J Clin Invest. 113:551–560. 2004. View Article : Google Scholar : PubMed/NCBI
13	Rogers DF: Airway goblet cell hyperplasia in asthma: hypersecretory and anti-inflammatory? Clin Exp Allergy. 32:1124–1127. 2002. View Article : Google Scholar : PubMed/NCBI
14	Kuperman DA, Huang X, Koth LL, et al: Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma. Nat Med. 8:885–889. 2002.PubMed/NCBI
15	Kuperman DA, Huang X, Nguyenvu L, Holscher C, Brombacher F and Erle DJ: IL-4 receptor signaling in Clara cells is required for allergen-induced mucus production. J Immunol. 175:3746–3752. 2005. View Article : Google Scholar : PubMed/NCBI
16	Black JL, Panettieri RA Jr, Banerjee A and Berger P: Airway smooth muscle in asthma: just a target for bronchodilation? Clin Chest Med. 33:543–558. 2012. View Article : Google Scholar : PubMed/NCBI
17	Bosse Y and Rola-Pleszczynski M: Controversy surrounding the increased expression of TGFβ1 in asthma. Respir Res. 8:662007.
18	Mohamed SA, Noack F, Schoellermann K, et al: Elevation of matrix metalloproteinases in different areas of ascending aortic aneurysms in patients with bicuspid and tricuspid aortic valves. Scientific World Journal. 2012:8062612012. View Article : Google Scholar : PubMed/NCBI
19	Yang J, Li Q, Zhou XD, Kolosov VP and Perelman JM: Naringenin attenuates mucous hypersecretion by modulating reactive oxygen species production and inhibiting NF-κB activity via EGFR-PI3K-Akt/ERK MAPKinase signaling in human airway epithelial cells. Mol Cell Biochem. 351:29–40. 2011.PubMed/NCBI
20	de Boer WI, Yao H and Rahman I: Future therapeutic treatment of COPD: struggle between oxidants and cytokines. Int J Chron Obstruct Pulmon Dis. 2:205–228. 2007.PubMed/NCBI